Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Doc Bones who wrote (1189)	9/27/1999 10:34:00 AM
From: LLCF	Read Replies (3) \| Respond to of 3202

Meanwhile, back at the ranch... INCY keeps cranking away: Monday September 27, 8:30 am Eastern Time Company Press Release SOURCE: Incyte Pharmaceuticals, Inc. Incyte and Schering AG Expand Genomic Database Partnership PALO ALTO, Calif., Sept. 27 /PRNewswire/ -- Incyte Pharmaceuticals, Inc. (Nasdaq: INCY - news) announced today the expansion of its relationship with Schering AG. Under the terms of the agreement, Schering AG will gain access to Incyte's LifeSeq® Gold assembled database in exchange for annual access fees. Incyte could receive future milestone payments and royalties on sales of products developed with Incyte technology and database information. Financial terms were not disclosed. LifeSeq Gold represents the Company's most comprehensive view of the human genome, and includes proprietary EST information, public human genome project data, full-length gene sequence as well as mapping data. All of these components are brought together using powerful world-class bioinformatics tools for analyzing and managing information. The amount of data included in LifeSeq Gold in conjunction with the powerful integrated analysis tools enables scientists to perform complex data analyses and queries within a single platform. ''We are pleased to be expanding our relationship with Schering AG to include access to LifeSeq Gold,'' said Roy A. Whitfield, Chief Executive Officer of Incyte. ''The integrated set of data and analytical tools in LifeSeq Gold provides scientists with the ability to streamline the research process and develop promising new drug therapies based on the knowledge of human gene sequences.'' Incyte Pharmaceuticals, Inc. is a leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases, genomic data management software, microarray-based gene expression services, related reagents and services. These products and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more information, visit Incyte's Web site at www.incyte.com. Except for the historical information contained herein, the matters set forth in this press release, are forward-looking statements within the meaning of the ''safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. For a discussion of factors that may cause results to differ, see Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 1999. Incyte disclaims any intent or obligation to update these forward-looking statements. SOURCE: Incyte Pharmaceuticals, Inc.